[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100431980":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":41,"locations":49,"responsibleParty":67,"collaborators":69,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":88,"minAge":89,"maxAge":24,"enrollmentInfo":90,"targetDuration":24,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":24,"overallStatus":52,"whyStopped":24,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Aventyn, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Subjects Hospitalized with a Primary Diagnosis of ADHF or Acute MI","EXPERIMENTAL","Phase 1 subjects 18 years or above hospitalized with a primary diagnosis of ADHF or acute MI. Patients will measure their vitals Weight, Sitting BP, Fluid Status, Heart Rate, Respiration Rate each morning for 30 days after discharge. The monitoring of this data of each patient daily will be done by dedicated H2O care team and hospitalist. The hospitalist will coordinate with the patient, the home health team, SNFs and the cardiologists as needed to correct\u002Ftreat any major abnormalities picked up by the remote monitoring system in order to prevent readmissions. Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.",[13],"Other: COMPASSION Digital Biomarker",{"label":15,"type":10,"description":16,"interventionNames":17},"Subjects Testing Positive Covid-19 Antigen Test","Phase 2 subjects 50 years or older with positive Covid-19 antigen test and one other risk factor as mentioned in the comorbid section of workflow will be enrolled in this arm of the study. Subjects will be randomized within 48 hours of Covid-19 antigen positive status. Patients will measure their vitals Weight, Sitting BP, Fluid Status, Heart Rate, Respiration Rate each morning for 30 days after discharge. The monitoring of this data of each patient daily will be done by dedicated H2O care team and hospitalist. The hospitalist will coordinate with the patient, the home health team, SNFs and the cardiologists as needed to correct\u002Ftreat any major abnormalities picked up by the remote monitoring system in order to prevent readmissions. Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"OTHER","COMPASSION Digital Biomarker","Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.",[9,15],null,[26,30,34,38],{"name":27,"affiliation":28,"role":29},"Kris Vijay, MD","Abrazo Arizona Heart","STUDY_CHAIR",{"name":31,"affiliation":32,"role":33},"Raj Bhat, MD","Pioneer Hospitalists","STUDY_DIRECTOR",{"name":35,"affiliation":36,"role":37},"Zaki Lababidi, MD","Gilbert Cardiology","PRINCIPAL_INVESTIGATOR",{"name":39,"affiliation":40,"role":37},"Ashok Solsi, MD","Premier Cardiovascular Center",[42,47],{"name":43,"role":44,"phone":45,"phoneExt":24,"email":46},"Navin Govind","CONTACT","2317942328","vitalbeat@aventyn.com",{"name":48,"role":44,"phone":24,"phoneExt":24,"email":24},"Sharolynn Mclurg",[50],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Multiple Locations","RECRUITING","Phoenix","Arizona","85016","United States","US",{"type":59,"coordinates":60},"Point",[61,62],-112.07404,33.44838,{"lat":62,"lon":61},[65],{"name":66,"role":44,"phone":24,"phoneExt":24,"email":24},"Puja Chandler",{"type":68,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[70,73,75,77],{"name":71,"class":72},"TwinEpidemic","UNKNOWN",{"name":74,"class":20},"Arizona State University",{"name":76,"class":6},"Intel Corporation",{"name":78,"class":72},"Heart Health Organization East Valley","100431980","care-coordination-to-assess-improvement-in-outcomes-in-hospital-readmissions-100431980",false,"NCT04905160","Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions","Care cOordination Using Mobile Technology to Enhance Patient Empowerment in Acute Comorbidities to aSSess Improvement in Outcomes in Hospital readmissioNs","COMPASSION","Inclusion Criteria:\n\nMen and women over 18 years of age are included. Eligible subjects must be hospitalized with a primary diagnosis of ADHF or acute MI. The diagnosis of HF is established by the presence of typical symptoms, signs, and objective evidence of pulmonary congestion, elevated BNP or N-terminal pro B-type natriuretic peptide (NT-pro BNP) or impaired cardiac function. Acute MI is diagnosed by presence of chest pain, arm pain, or dyspnea with elevated Troponin and\u002For EKG changes suggestive of Acute coronary syndrome requiring intervention or optimal medical therapy.\n\nExclusion Criteria:\n\n1. Study informed consent will be obtained before enrollment in the study for Phase 1 and Phase 2\n2. All subjects 18 years or above will be a criteria for inclusion for Phase 1\n3. For Phase 2, men and women 50 years or older with positive Covid19 antigen test and one other risk factor as mentioned in the comorbid section of workflow will be enrolled in the intervention arm of the study;\n4. For phase 2, subjects should be able to be randomized within 48 hours of Covid19 antigen positive status\n5. Patients considered unreliable by the investigator concerning the requirements for follow-up visits",true,"ALL","18 Years",{"count":91,"type":92},1000,"ESTIMATED","INTERVENTIONAL",[95],"NA","Heart failure is a syndrome that is defined by distinctive clinical, hemodynamic, and neurohormonal findings. HF represents a final common pathway for many different cardiovascular diseases, including coronary disease, hypertension, Valvular disease, and many primary heart muscle diseases. Clinically, HF patients experience dyspnea, fatigue and diminished exercise tolerance, reflecting elevated left and\u002For right ventricular filling pressures and decreased cardiac output.",[98,99,100],"Heart Failure","ADHF","Acute MI","2024-03-19",{"date":103,"type":104},"2024-03-20","ACTUAL",{"date":106,"type":104},"2021-02-18",{"date":108,"type":92},"2026-12-22",{"name":5,"class":6},1]